Intravenous and Oral Sulodexide Versus Coagulation Activation Markers in Humans
To the Editor:
Sulodexide is a glycosaminoglycan medication consisting of 80% fast-moving heparin (containing heparan sulfate) and 20% dermatan sulfate. Because of low molecular weight of both fractions, its intestinal absorption is feasible and the drug is commercially available in oral and parenteral form. 1, 2 It shows particular benefit in the prevention/treatment of diabetic nephropathy, cardiovascular diseases, and deep vein thrombosis, 3, 4 and (as reported recently also in this journal) it exhibits some interesting pleiotropic properties. [5] [6] [7] The hemostatic actions of intravenous (IV) sulodexide generally resemble those of unfractionated heparin, but the heparinoid drug has relatively reduced effects on global coagulation and occurrence of bleeding events. [1] [2] [3] [4] Detailed anticoagulant effects of oral sulodexide in humans are not completely elucidated, but the treatment is clinically safe, beneficial, and attractive because of no need for laboratory monitoring. [1] [2] [3] [4] So far no data on the influence of sulodexide on coagulation activation markers such as prothrombin activation fragment 1þ2 (F1þ2) and thrombin-antithrombin (TAT) complexes are available, as indicated by PubMed and Scopus database searches. Therefore, we studied the effects of IV injections of sulodexide and its 2-week oral (PO) administration on plasma levels of these thrombogenesis markers in humans in a prospective open-label pilot trial.
A total of 11 healthy volunteer men aged 30.4 + 1.16 years were enrolled, as described previously. 5, 7 The study conformed to the Declaration of Helsinki and was approved by our institutional Ethics Committee. On its initiation (day 1), fasted venous blood samples (T0) were obtained with no stasis puncture into citrated vacutainers. Then, sulodexide (Vessel Due F, Alfa Wassermann SpA, Bologna, Italy) was injected IV at a dose of 1.200 lipoprotein lipase releasing units (LRU). Afterward, the participants remained ambulatory and were allowed habitual water intake; the consecutive blood samples were drawn after 10 minutes (T10) and 120 minutes (T120). As the next step, they were asked to take oral sulodexide at a dose of 500 LRU twice a day (bid) for 12 consecutive days. On day 7, blood samples were obtained at T0; then the participants ingested 500 LRU of sulodexide and the sampling was repeated at T120. On day 14, no usual morning oral dose was given and 1200 LRU of the drug was again injected IV; further procedures and timing of the blood drawn strictly followed those used on day 1. After that, the study was terminated. The daily oral sulodexide dose of 1.000 LRU was chosen based on that used in a majority of previous clinical trials. 3, 4 The IV dose of 1.200 LRU (recommended as a loading dose) was selected as part of a phase I study. 3, 4 The actual oral dose used in this trial was 12.0 + 1.57 LRU/kg per day and the IV dose was 14.4 + 1.88 LRU/kg. Drug compliance was evaluated by questioning the participants and counting the capsules; the study period and follow-up were uneventful. Plasma levels of thrombogenesis markers F1þ2 and TAT were quantified with immunoenzymatic Enzygnost Micro kits from Dade Behring, Marburg, Germany. The intraplate and interplate coefficients of variations were <7%. All data were normally distributed, expressed as means +1 SD, and analysis of variance (ANOVA) for repeated measures with the post hoc Newman-Keuls test, paired Student t test, and Pearson regression analysis were used when appropriate. The 2-sided P values <.05 were considered significant.
Plasma F1þ2 levels significantly changed following initial IV sulodexide injection (F ¼ 24.6, P < .0001; Figure 1A ). They were 0.93 + 0.19 nmol/L at T0, 0.92 + 0.13 nmol/L and unchanged at T10, and at T120 they decreased by a mean of 40% (vs. baseline) to 0.51 + 0.16 nmol/L (P ¼ .0001). Plasma TAT levels remained unchanged and were 1.24 + 0.27 mg/L, 1.26 + 0.32 mg/L, and 1.19 + 0.32 mg/L, respectively. Following oral sulodexide administration on day 7, both plasma markers remained stable when measured after 120 minutes (both P < .715). On day 14, IV sulodexide injection resulted in another decrease in F1þ2 (F ¼ 6.85, P ¼ .004) and no change in TAT (F ¼ 2.14, P ¼ .135). The F1þ2 levels were 0.55 + 0.19 nmol/L at T0, 0.51 + 0.15 nmol/L at T10, and decreased to 0.32 + 0.14 nmol/L at T120 (by 38% vs. baseline, P ¼ .008). Notably, on the initial injection, weak negative associations between IV sulodexide dose per kg body weight (BW) and plasma F1þ2 levels at T120 (r ¼ À.613, P ¼ .032, Figure 1B ) and between the dose and the percentage decrease in plasma F1þ2 at T120 versus T0 (r ¼ À.540, P ¼ .047) were identified. On the repeated injection, the correlations were also negative but not significant (both P < .606). Interestingly, baseline (T0) F1þ2 levels significantly decreased during the sulodexide trial (F ¼ 17.7, P < .0001; Figure 1C ), while those of TAT remained stable (F ¼ 1.0, P ¼ .379). Compared to study initiation (0.93 + 0.19 nmol/L), the F1þ2 values on day 14 were lower by a median of 30% (P ¼ .0001) and amounted to 0.55 + 0.19 nmol/L.
Our results point to several new aspects of sulodexide use in humans. First, IV administration of sulodexide in a dose of 1.200 LRU results in a marked decrease in plasma F1þ2 levels, which indicates a state of intense anticoagulation achieved as early as after 2 hours. This effect is comparable to that observed after 5 hours from subcutaneous administration of 150 IU/kg of unfractionated heparin (*10.000 IU) or 75 IU/kg of dalteparin (*5.000 IU). 8 Interestingly, the anticoagulant effect of IV sulodexide was closely dose-dependent on initial exposure to the drug and evident on rechallenge following oral treatment, but after that it became unrelated to the dose; this issue needs further investigations. Another result of plausible clinical importance is that the standard oral dose of sulodexide also leads to significant suppression of plasma F1þ2 levels and that the effect is exerted not earlier than after 1 week. Regarding unchanged levels of TAT-the other thrombogenesis marker followed during sulodexide administration, our finding was unexpected but in line with previous reports of lack of suppression of TAT formation under influence of heparin. 8, 9 This may be due to the fact that antithrombin is not the only thrombin binding protein (ie, thrombomodulin, heparin cofactor II) and that a mixture of heparan and dermatan sulfate contained in sulodexide may induce catalytic formation of TAT complexes, 10 analogously to the effect of heparin. 8, 9, 11 The discrepancy may also result from different half-life times of the thrombogenesis markers (F1þ2 *90 minutes, TAT *15 minutes). 12 Our results however imply that plasma F1þ2 is a better marker than TAT for actual thrombin generation during sulodexide administration and indirectly supports the previous efforts to use the F1þ2 assay for monitoring various antithrombotic therapies. 13, 14 The issue that may attract practicing clinicians to more extensive use of sulodexide (which could be envisioned as ''oral heparin'') is that in an advantage to regular heparin this heparinoid compound is also active against fibrin-bound thrombin within vascular clots due to its marked contents of dermatan sulfate. 15, 16 In conclusion, both IV and oral administration of sulodexide induces marked suppression of plasma F1þ2 in healthy humans, indicating a state of significant anticoagulation. The drug deserves further studies as a therapeutic alternative to heparin or oral anticoagulants.
